Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases
Authors:
Open Access
- 8 April 2024
- journal article
- research article
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (6) , 741-750
Abstract
Purpose: Percutaneous hepatic perfusion with melphalan (M-PHP) is a minimally invasive therapy with proven efficacy in patients with uveal melanoma (UM) liver metastases. M-PHP is associated with a short hospital admission time and limited systemic side effects. In this study, we assessed quality of life (QoL) in UM patients treated with M-PHP. Materials and Methods: A prospective, single-center study including 24 patients treated with M-PHP for UM metastases to the liver. QoL questionnaires were collected at baseline, on day 2/3 after M-PHP, and on day 7 and day 21 after M-PHP, according to study protocol. The results were scored according to EORTC-QLQ C30 global health status (GHS), functional scales, and symptom scales. The difference in scores at baseline and subsequent time points was analyzed with the Wilcoxon signed-rank test and multiple testing Bonferroni correction. Adverse events (AE) were registered up to 30 days after M-PHP according to CTCAE v5.0. Results: Twenty-four patients (14 males; median age 63.0 years) completed 96 questionnaires. Most scores on all scales declined on day 2/3 after M-PHP. On day 21 after M-PHP, 12 out of 15 scores returned to baseline, including median GHS scores. Three variables were significantly worse on day 21 compared to baseline: fatigue (6–33; p = 0.002), physical functioning (100 vs 86.7; p = 0.003), and role functioning (100 vs 66.7; p = 0.001). Grade 3/4 AEs consisted mainly of hematological complications, such as leukopenia and thrombopenia. Conclusion: M-PHP causes fatigue and a decline in physical and role functioning in the 1st weeks after treatment, but GHS returns to baseline levels within 21 days. Level of Evidence 3: Cohort study. GraphicalKeywords
This publication has 26 references indexed in Scilit:
- Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidenceCancer Treatment Reviews, 2022
- Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled AnalysisCardioVascular and Interventional Radiology, 2022
- Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal MelanomaRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2021
- Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in FranceCardioVascular and Interventional Radiology, 2020
- Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II TrialCardioVascular and Interventional Radiology, 2019
- Safety and efficacy of chemosaturation in patients with primary and secondary liver tumorsJournal of Cancer Research and Clinical Oncology, 2017
- Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with MelphalanCardioVascular and Interventional Radiology, 2017
- Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre StudyCardioVascular and Interventional Radiology, 2017
- Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver MalignanciesCardioVascular and Interventional Radiology, 2015
- Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal MelanomaArchives of Ophthalmology (1950), 2005